PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY News PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY
PADAGIS ANNOUNCES THE FIRST LAUNCH OF AN OVER-THE-COUNTER NALOXONE NASAL SPRAY IN THE UNITED STATES News PADAGIS ANNOUNCES THE FIRST LAUNCH OF AN OVER-THE-COUNTER NALOXONE NASAL SPRAY IN THE UNITED STATES
Padagis announces the acquisition of 17,000 square meter facility in Yerucham, Israel News Padagis announces the acquisition of 17,000 square meter facility in Yerucham, Israel
PADAGIS ANNOUNCES TWO FIRST-TO-FILE ANDA SUBMISSIONS News PADAGIS ANNOUNCES TWO FIRST-TO-FILE ANDA SUBMISSIONS
Padagis Announces FDA Approval and Launch of A-Rated Generic Version of Uceris® (Budesonide 2mg Rectal Foam) News Padagis Announces FDA Approval and Launch of A-Rated Generic Version of Uceris® (Budesonide 2mg Rectal Foam)
Padagis announces the relaunch of Bacitracin Ophthalmic Ointment News Padagis announces the relaunch of Bacitracin Ophthalmic Ointment
Padagis announces the launch of Brimonidine Topical Gel, 0.33% News Padagis announces the launch of Brimonidine Topical Gel, 0.33%
Recent Comments